Davis Polk advised the sole book-running manager of a $387.5 million SEC-registered offering of 5,000,000 shares of common stock of Alnylam Pharmaceuticals, Inc. Alnylam’s common stock is listed on NASDAQ under the symbol “ALNY.”
Headquartered in Cambridge, Massachusetts, and founded in 2002, Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers. ONPATTRO (patisiran) lipid complex injection, available in the United States for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, is Alnylam’s first U.S. FDA-approved RNAi therapeutic.
The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associates Dan Gibbons and Arisa Akashi. Associate Jason J. Bang provided intellectual property and technology advice. The tax team included partner Rachel D. Kleinberg and associate Elina Khodorkovsky. Members of the Davis Polk team are based in the New York and Northern California offices.